Diseases of Mineral Metabolism and Bone: Emerging Therapeutics for Postmenopausal Osteoporosiss

摘要: The pharmacological management of postmenopausal osteoporosis (PMO) was heralded by the registration injectable calcitonin, an antiresorptive agent that in nasal formulation shown to be effective reduce risk incident vertebral fractures [14]. Other agents, with different mechanisms action inhibit bone resorption, then followed for PMO: estrogen, bisphosphonates, selective estrogen receptor modulators, and most recently, denosumab [6, 17, 20, 39, 40] Among these bisphosphonates became, and, date, still are, dominant utilized treat PMO [43, 47, 62, 66, 70]. Bisphosphonates this year celebrate their 40th anniversary since introduction into clinical medicine [61].